Overview of Dr. Cherng
Dr. Hua-Jay Cherng is a New York-based oncologist with a subspecialty in hematologic oncology. He has been educated and trained at prestigious institutions, starting at Case Western Reserve University School of Medicine, followed by his internship and residency at University of Pennsylvania Health System, and his fellowship at University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Professional experience ranges from Resident Physician at the Hospital of the University of Pennsylvania to Clinical Fellow at University of Texas M.D. Anderson Cancer Center. His expertise lies in internal medicine and medical oncology. He has an impressive list of publications in esteemed journals, discussing various aspects of lymphoma, DLBCL treatment, and CAR T-cell therapy.
Office
161 Fort Washington Avenue
Garden Level
New York, NY 10032
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2016 - 2019
- Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2016 - 2019
- Case Western Reserve University School of MedicineClass of 2016
Certifications & Licensure
- NY State Medical License 2022 - 2025
- TX State Medical License 2019 - 2024
- PA State Medical License 2016 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 11 citationsImpact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.Paolo Strati, Andrew P Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das
Leukemia. 2022-11-01 - 27 citationsRisk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.Hua-Jay J Cherng, Ryan Sun, Bryant Sugg, Russell Irwin, Haopeng Yang
Blood. 2022-08-04 - 5 citationsPositron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.Hua-Jay J Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad
British Journal of Haematology. 2023-01-01
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: